APX 004

Drug Profile

APX 004

Alternative Names: APX004; DYW 101

Latest Information Update: 20 Mar 2014

Price : $50

At a glance

  • Originator Epitomics
  • Developer Apexigen; Gansu Duyiwei Biological Pharmaceutical
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 20 Mar 2014 Preclinical development is ongoing
  • 06 Mar 2012 Preclinical trials in Cancer in China (Parenteral)
  • 12 Aug 2010 Epitomics spins-off a new company called Apexigen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top